Twist Bioscience
455 Mission Bay Blvd South
San Francisco
California
94158
United States
295 articles about Twist Bioscience
-
Twist Bioscience to Present at Two Investor Conferences in September
8/30/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Jim Thorburn, CFO of Twist Bioscience, will present at two investor conferences in September:
-
Twist Bioscience Launches Long Oligos to Fuel Drug Development, DNA Data Storage and Gene Editing Research
7/29/2019
Oligonucleotides up to 300 Bases with Exceptionally Low Error Rate
-
Twist Bioscience Enhances DNA Storage Capabilities Through Agreement With Imagene SA
7/25/2019
Agreement Enables Twist to Securely Store DNA With Digital Data Encoded
-
Twist Bioscience to Report Fiscal 2019 Third Quarter Financial Results on Thursday, August 1, 2019
7/25/2019
The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company’s business.
-
Twist Bioscience Launches Mouse Exome to Power Genetic Research
6/17/2019
Twist Mouse Core Exome Panel is the most comprehensive, up-to-date tool for interrogation of the mouse exome, further enabling genetic research of this important model organism.
-
BioSpace Movers and Shakers, May 24
5/24/2019
Biopharma companies from across the globe strengthen their leadership teams with key executive appointments. -
Twist Bioscience Strengthens Board With Semiconductor and Storage Expert Nelson C. Chan
5/23/2019
Replaces Paul Conley on Board of Directors
-
Collaboration of Four Biotech Companies Showcases High Throughput DNA Assembly Platform for Diverse Applications
5/23/2019
The companies plan to host an event at Arzeda's headquarters in Seattle on Thursday, May 30th where they will demonstrate several tangible examples of how the integrated platform accelerated development of various products including a food and beverage sweetener as well as a key component in the next generation of plexiglass.
-
Twist Bioscience to Present at the UBS Global Healthcare Conference
5/16/2019
Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20th at 11:30 a.m. ET.
-
Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
5/13/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its upsized underwritten public offering of 4,312,500 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 562,500 shares of common stock in this offering.
-
Twist Bioscience Announces Pricing of $78.8 Million Public Offering of Common Stock
5/9/2019
Twist Bioscience Corporation announced the pricing of its underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $21.00 per share, before underwriting discounts and commissions.
-
Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress
4/30/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2019 ended March 31, 2019.
-
Twist Bioscience Announces Synthetic DNA Biosecurity Publication in Frontiers
4/25/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a new biosecurity publication titled ‘Next Steps for Access to Safe, Secure DNA Synthesis’,
-
Twist Bioscience and iGEM Partner to Provide Synthetic DNA for iGEM Competition and Registry
4/15/2019
Collaboration to change the way iGEM Competition teams contribute to the Registry of Standard Biological Parts, a free online database for synthetic biologists.
-
Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics
4/11/2019
Pandion Therapeutics is a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease.
-
Twist Bioscience Customized Libraries for Biologics Discovery Highlighted at PEGS Boston 2019
4/9/2019
Proof-of-Concept Data Presented for GPCR Library and Antibody Optimization Solution
-
Twist Bioscience Adopts Battelle’s ThreatSEQ™ DNA Screening Web Service for Advanced Biosecurity
4/9/2019
Twist Bioscience continues its leadership in the field of biosecurity as the first to integrate the ThreatSEQ web service into its gene-length DNA screening pipeline.
-
Twist Bioscience and LakePharma Form Strategic Collaboration to Provide Antibody Discovery and Development Services
4/4/2019
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers.
-
Twist Bioscience Announces Presentations and User Group Meeting at PEGS Boston 2019
4/1/2019
Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to Deliver Keynote Address
-
Twist Bioscience to Present at Cowen 39th Annual Healthcare Conference
3/5/2019
Twist Bioscience Corporation announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the 39th Annual Cowen Healthcare Conference on Tuesday, March 12th at 11:20 a.m.